Abstract:Background: Non-surgical cytological specimens are adequate not only for accurate histological subtyping but also for molecular profiling. A modified amplification refractory mutation system polymerase chain reaction (ARMS PCR), known as SuperARMS PCR, was improved by optimizing the primers designation, which provides a higher sensitivity and specificity approach for free plasma DNA detection. It is unclear whether SuperARMS PCR detects epidermal growth factor receptor (EGFR) mutations in cytology samples. The aim of this study was to compare the EGFR mutations detected by ARMS PCR and SuperARMS PCR in cytology samples derived from advanced non-small cell lung cancer (NSCLC) patients. Methods: From March 2016 to March 2018, a total of 234 cytological samples were obtained from primary or metastatic lesions of NSCLC, including 144 fine-needle aspirations (FNAs), 36 endobroncheal ultrasonography (EBUS) FNAs, 36 transbronchial needle aspirations (TBNAs) and 18 pleural effusion (PLEs). EGFR mutations were simultaneously detected using an ADx-ARMS EGFR kit (Amoy Diagnostics CO., ltd., Xiamen, China) and an ADx-SuperARMS EGFR kit (Amoy Diagnostics CO., ltd., Xiamen, China). Digital droplet PCR (ddPCR) and next-generation sequencing (NGS) were further used to verify the EGFR mutant inconsistent samples. Results: All of the 234 patients with advanced or recurrent NSCLC were diagnosed and assessed by two cytopathologists, and their EGFR mutation statuses were successfully detected by ARMS and SuperARMS. Importantly, the SuperARMS and ARMS methods showed a highly concordant result of 94.0% (220/234) (95%CI: 85.0, 95.0%). The positive rate of the SuperARMS was higher than the ARMS in the cytology samples for EGFR detection (46.2% vs. 40.2%). The specific EGFR mutation sites in 16 samples (6.8%) were not completely consistent between the SuperARMS and ARMS. A total of 14 patients showed EGFR mutations when detected by SuperARMS, but by ARMS there were EGFR wild-type. Two patients were detected as having one more EGFR mutation site by SuperARMS than by ARMS. ddPCR and NGS were used to further confirm the EGFR mutations in these inconsistent samples. Eight samples had the same mutation results as the SuperARMS, and 6 samples were not verified because the remaining DNA was insufficient. A total of 78 EGFR mutation patients received Tyrosine Kinase Inhibitor (TKI) treatment. The overall objective response rate (ORR) was 88.5% (69/78) for EGFR TKI treatment. Conclusion: SuperARMS showed a high sensitivity and specificity for EGFR detection and thus, is expected to become a routine test in the clinic to be used as a widely available, easy-to-operate and sensitive method for EGFR mutation detection in liquid-based cytology samples.

The Comparison of EGFR Mutation Detection in Clinical Biopsy Samples of Lung Cancer by ARMS and Direct Sequencing

A Comparison of ARMS and Direct Sequencing for EGFR Mutation Analysis and Tyrosine Kinase Inhibitors Treatment Prediction in Body Fluid Samples of Non-Small-Cell Lung Cancer Patients

Comparison Between ADx-ARMS and PCR-Sanger Sequencing for EGFR Mutation Detection in Small Biopsy Samples of Non Small Cell Lung Cancer

Detection of Epidermal Growth Factor Receptor Mutations in Small Specimens of Non-Small Cell Lung Cancer by Amplification Refractory Mutation System

A Prospective Comparison Study on EGFR Mutations by Direct Sequencing and ARMS in Completely Resected Chinese Non-Small Cell Lung Cancer with Adenocarcinoma Histology (ICAN).

Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients

Comparison of Different Methods for Detecting Epidermal Growth Factor Receptor Mutations in Peripheral Blood and Tumor Tissue of Non-Small Cell Lung Cancer As A Predictor of Response to Gefitinib

EGFR Gene Mutation and Methodological Evaluation in 399 Patients with Non-small Cell Lung Cancer

Comparison of the SuperARMS and ARMS for detecting EGFR mutations in liquid-based cytology specimens from NSCLC patients

Analysis of epidermal growth factor receptor gene mutations in 406 small biopsy samples of lung cancer

Comparison of Egfr Mutation Status Between Plasma and Tumor Tissue in Non-Small Cell Lung Cancer Using the Scorpion Arms Method and the Possible Prognostic Significance of Plasma Egfr Mutation Status

Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations.

A novel ARMS-based assay for the quantification of EGFR mutations in patients with lung adenocarcinoma

Comparison of EGFR Mutations Detected by LNA-ARMS PCR in Plasma Ctdna Samples and Matched Tissue Sample in Non-Small Cell Lung Cancer Patients.

Correlation analysis of serum free DNA EGFR mutation and EGFR-TKI response in lung cancer patients

Detection of EGFR, KRAS, BRAF, EML4-ALK fusion genes by ARMS and NGS in patients with non-small cell lung cancer

Quantitative Test of Mutant Egfr and Its Effect on Efficacy of Egfr Tki in Advanced Nsclc

[Comparison of epidermal growth factor receptor (EGFR) gene T790M mutation by droplet digital PCR and Super-ARMS PCR in plasma ctDNA samples of non-small cell lung cancer patients with the resistance to EGFR-tyrosine kinase inhibitor]

Detection of EGFR Gene Mutation in Lung Adenocarcinoma by ARMS and Its Clinical Significance

Comprehensive Analysis of NGS and ARMS-PCR for Detecting EGFR Mutations Based on 4467 Cases of NSCLC Patients

Detection of EGFR gene mutations with mutation-speciifc immunohistochemistry in non-small cell lung cancer